Findings of a Biosimilar Trastuzumab Study in Patients with HER2-Positive Breast Cancer

September 21, 2016
Francisco Esteva

Francisco Esteva, director, breast medical oncology program, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the findings of a biosimilar trastuzumab study in patients with HER2-positive breast cancer.